Design Therapeutics, Inc.
DSGNHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeDesign Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. At a $947.5M market cap, Design Therapeutics, Inc. ranks as a small-cap company within healthcare. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.
Market Cap
$947.5M
Beta
1.66
P/E (TTM)
—
P/E (Fwd)
-9.50
EPS (TTM)
$-1.18
EPS (Fwd)
$-1.59
ROE
-34.1%
ROA
-22.5%
Cash
$207.4M
Total Debt
$2.7M
Free CF
-$32.4M
52W Change
128.0%
Annual Financials
Cash vs Debt
Where DSGN stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, DSGN finished 26.06% above its 150-day moving average ($12.32) and 34.34% above its 200-day moving average ($11.56). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is DSGN overbought or oversold?
At the September 3, 2026 close, DSGN's RSI(14) was 63.5, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Design Therapeutics, Inc. holds $207.4M in cash against $2.7M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$32.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -34.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
Design Therapeutics, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing DSGN.